PDF(Pubmed)
Abstract：
UNASSIGNED: Many of the vaccines developed for COVID-19 have been approved for clinical emergency use before their safety and preclinical studies have been completed. The main aim of this study was to investigate the effects of an inactivated SARS-CoV-2 virus vaccine (Vero cells) on renal function in Balb/C Albino mice.
UNASSIGNED: 21 healthy, 6-8 week old BALB/c male mice were divided into three equal groups, and 0.10 mL of intramuscular saline equal to the vaccine dose volume was administered to the first group. To the second group, a single dose of 0.10 mL 120 U of Vero cell inactive SARS COV-2 vaccine was administered intramuscularly. Group 3 received two consecutive doses of 0.10 mL 120 U intramuscular Vero cell inactive SARS COV-2 vaccine, 14 days apart. After administration, the clinical status, fecal and urine status, nutritional status and kidney histopathology of the mice were evaluated.
UNASSIGNED: It was determined that no acute toxic symptoms were observed in the mice administered the vaccine, they were in good condition, and there was no significant stimulatory reaction related to the vaccine in the tissues of the injected local area. There was no difference in feed consumption, water consumption, and body weight gains between the control group, the groups that received a single dose of vaccine, and the groups that received two doses of vaccine (p>0.05). No difference was found between the groups when urine and feces amounts were compared (p>0.05). No difference was found between the groups when urinary urea, creatinine, and serum BUN, creatinine levels were compared (p>0.05). No difference was found in the histopathological evaluation of the kidneys between the groups (p>0.05).
UNASSIGNED: In conclusion, single or repeated injections of the SARS-CoV-2 vaccine (Vero cells) into mice were found to have no adverse effects on the animals\' overall clinical health, performance abilities and kidneys.
UNASSIGNED: 21 healthy, 6-8 week old BALB/c male mice were divided into three equal groups, and 0.10 mL of intramuscular saline equal to the vaccine dose volume was administered to the first group. To the second group, a single dose of 0.10 mL 120 U of Vero cell inactive SARS COV-2 vaccine was administered intramuscularly. Group 3 received two consecutive doses of 0.10 mL 120 U intramuscular Vero cell inactive SARS COV-2 vaccine, 14 days apart. After administration, the clinical status, fecal and urine status, nutritional status and kidney histopathology of the mice were evaluated.
UNASSIGNED: It was determined that no acute toxic symptoms were observed in the mice administered the vaccine, they were in good condition, and there was no significant stimulatory reaction related to the vaccine in the tissues of the injected local area. There was no difference in feed consumption, water consumption, and body weight gains between the control group, the groups that received a single dose of vaccine, and the groups that received two doses of vaccine (p>0.05). No difference was found between the groups when urine and feces amounts were compared (p>0.05). No difference was found between the groups when urinary urea, creatinine, and serum BUN, creatinine levels were compared (p>0.05). No difference was found in the histopathological evaluation of the kidneys between the groups (p>0.05).
UNASSIGNED: In conclusion, single or repeated injections of the SARS-CoV-2 vaccine (Vero cells) into mice were found to have no adverse effects on the animals\' overall clinical health, performance abilities and kidneys.
摘要：
■许多为COVID-19开发的疫苗在其安全性和临床前研究完成之前已被批准用于临床急诊。这项研究的主要目的是研究灭活的SARS-CoV-2病毒疫苗（Vero细胞）对Balb/C白化病小鼠肾功能的影响。
■21健康，将6-8周龄BALB/c雄性小鼠分为3组,第一组给予等于疫苗剂量体积的0.10mL肌内生理盐水.对第二组来说，肌内注射单剂量0.10mL120UVero细胞失活的SARSCOV-2疫苗.第3组接受两次连续剂量的0.10mL120U肌内Vero细胞灭活SARSCOV-2疫苗，相隔14天给药后,临床状况，粪便和尿液状态，评估小鼠的营养状况和肾脏组织病理学。
■确定在施用疫苗的小鼠中未观察到急性毒性症状，他们状况良好，注射局部组织中没有明显的与疫苗相关的刺激反应。饲料消耗没有差异，用水量,对照组之间的体重增加，接受单剂量疫苗的群体，和接受两剂疫苗的组(p>0.05)。当比较尿液和粪便量时,组间没有发现差异(p>0.05)。两组之间在尿尿素时没有发现差异，肌酐,和血清BUN,比较肌酐水平(p>0.05).两组之间肾脏的组织病理学评估无差异（p>0.05）。
■总而言之，对小鼠单次或重复注射SARS-CoV-2疫苗（Vero细胞）对动物的整体临床健康无不良影响，表现能力和肾脏。
■21健康，将6-8周龄BALB/c雄性小鼠分为3组,第一组给予等于疫苗剂量体积的0.10mL肌内生理盐水.对第二组来说，肌内注射单剂量0.10mL120UVero细胞失活的SARSCOV-2疫苗.第3组接受两次连续剂量的0.10mL120U肌内Vero细胞灭活SARSCOV-2疫苗，相隔14天给药后,临床状况，粪便和尿液状态，评估小鼠的营养状况和肾脏组织病理学。
■确定在施用疫苗的小鼠中未观察到急性毒性症状，他们状况良好，注射局部组织中没有明显的与疫苗相关的刺激反应。饲料消耗没有差异，用水量,对照组之间的体重增加，接受单剂量疫苗的群体，和接受两剂疫苗的组(p>0.05)。当比较尿液和粪便量时,组间没有发现差异(p>0.05)。两组之间在尿尿素时没有发现差异，肌酐,和血清BUN,比较肌酐水平(p>0.05).两组之间肾脏的组织病理学评估无差异（p>0.05）。
■总而言之，对小鼠单次或重复注射SARS-CoV-2疫苗（Vero细胞）对动物的整体临床健康无不良影响，表现能力和肾脏。
